In nearly 20 years, aside from cholinesterase inhibitors, memantine is the only drug approved for the treatment of Alzheimer's disease (AD). Memantine is an uncompetitive N-methyl-D-aspartate ...

JPMorgan upgraded Amneal Pharmaceuticals (AMRX) to Overweight from Neutral with a price target of $12, up from $9. The firm cites the Crexont ...

抑郁症是一种常见的精神障碍。单胺类抗抑郁药是一线治疗方案，但其对部分患者仍然无效。协同调节神经炎症和神经可塑性是治疗抑郁症的主要策略。有鉴于此，四川大学高会乐教授开发了一种靶向炎症的小胶质细胞仿生系统PDA-Mem@M，并将其用于治疗抑郁症。

It comes after the news this week that BBC Radio Scotland presenter Janice Forsyth has stepped down after being diagnosed ...

After hours: February 21 at 6:29:36 PM EST Loading Chart for AMRX ...

MS can impact your vision in various ways. It can make your vision hazy or give you double vision. It can also cause your eyes to move involuntarily. In some cases, it can even lead to blindness ...

Amneal Pharmaceuticals (AMRX) announced the launch of mesalamine 800 mg delayed-release tablets, an aminosalicylate indicated for the treatment ...

memantine, or both – as well as ApoE4 status and geographical region. Clarity AD’s phase 3 primary endpoint was change from baseline at 18 months in the CDR-SB (Clinical Dementi Rating Sum of ...

After hours: February 21 at 6:29:36 p.m. EST ...

Ed is a neurologist at the National Hospital for Neurology and Neurosurgery, London, UK, and a Professor of Neurology at University College London where he is Associate Director of the Huntington’s ...